All Articles

AABB restarts a major Mexican gold drill program, but its true strategy lies in a hybrid model weaving physical mining with a controversial crypto empire.

Marga.ai partners with leadership guru Aviad Goz to create an 'Authentic Human AI' mentor, betting that judgment, not just data, is the next great digital asset.

While many media giants chase national scale, Gray Media’s award-winning localism reveals a powerful strategy: treating community trust as a critical asset.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

Sorenson Communications' national workplace recognition highlights a critical strategy: investing in people to drive innovation and quality in accessible communications.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

Pledge Software's Pactman has launched a free nonprofit compliance report, aiming to disrupt the slow, costly verification market dominated by giants like Candid/GuideStar.

In an era of hyperscale dominance, InMotion Hosting doubles down on owned infrastructure, using a new SDN fabric to offer greater control and performance.

The Ohio manufacturer's management buyout signals a shift from private equity cycles to long-term agility in a booming precision components market.

GlobalFoundries and Qualinx just built a secure, Europe-only chip pipeline. It's a major win for the EU's tech sovereignty—and a warning shot to rivals.

evyAI is offering its full AI sales agent for free until summer 2026, challenging the subscription model. We dig into the strategy, the risks, and what it means for you.

As the Indian media giant turns ten, its biggest bet isn't on the big screen. A deep dive into its massive microdrama acquisition and global strategy.

As official Semiquincentennial plans face political division, a new independent website, Wisdomof250.com, aims to unite the nation’s celebrations.

With only 4% of US pets insured despite soaring vet costs, a new partnership signals a major shift. Is embedding insurance the key to this untapped market?

The viral foldable home company BOXABL has secured its Nasdaq listing via a SPAC merger. But with a massive valuation and minimal cash from the deal, can it deliver?

The asset manager's May report reveals $3.3B in net inflows, driven by a major target date fund win, underscoring its market resilience and leadership.

Organon's FDA nod for TOFIDENCE in critical care isn't just a clinical win. It's a calculated move to capture market share and challenge high-cost biologics.

A junior miner revives a historic Utah uranium district, blending old data with new tech. Is this a savvy play for the nuclear boom or a speculative gamble?

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.